News Merck & Co in pole position for Ebola vaccine approval as FD... The FDA is to review Merck & Co’s Ebola vaccine, giving the US pharma a chance to grab a first approval within six months.
News BMS' Opdivo misses target in aggressive brain cancer trial It’s never good news when a drug firm posts an “update” about a phase 3 trial, and Bristol-Myers Squibb’s PR team have had to issue news of another trial disappointment from the misfiring c
News AZ/MSD’s PARP inhibitor shows promise as first-line ovarian ... AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of advanced ovarian cancer.
News Merck & Co and others test vaccine delivery drone Merck & Co is among the partners behind a consortium testing the potential to deliver temperature-controlled medicines and vaccines using a drone.
News US pharma tariffs of up to 100% finalised by Trump Trump signs his pharma tariffs executive order, which won't affect most large pharma groups but could deal a hefty blow to smaller companies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
